Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
SYRS

SYRS - Syros Pharmaceuticals Inc Stock Price, Fair Value and News

5.78USD+0.20 (+3.58%)Market Closed

Market Summary

SYRS
USD5.78+0.20
Market Closed
3.58%

SYRS Stock Price

View Fullscreen

SYRS RSI Chart

SYRS Valuation

Market Cap

149.1M

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

15.01

Price/Free Cashflow

-1.43

SYRS Price/Sales (Trailing)

SYRS Profitability

Return on Equity

-959.64%

Return on Assets

-107.25%

Free Cashflow Yield

-69.85%

SYRS Fundamentals

SYRS Revenue

Revenue (TTM)

9.9M

Rev. Growth (Yr)

-88.71%

Rev. Growth (Qtr)

-89.73%

SYRS Earnings

Earnings (TTM)

-144.5M

Earnings Growth (Yr)

84.41%

Earnings Growth (Qtr)

94.24%

Breaking Down SYRS Revenue

52 Week Range

2.725.80
(Low)(High)

Last 7 days

-7.0%

Last 30 days

4.1%

Last 90 days

-11%

Trailing 12 Months

91.1%

How does SYRS drawdown profile look like?

SYRS Financial Health

Current Ratio

3.01

Debt/Equity

1.97

Debt/Cashflow

-3.5

SYRS Investor Care

Shares Dilution (1Y)

29.78%

Diluted EPS (TTM)

-5.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202313.6M12.4M11.2M9.9M
202224.1M25.2M23.4M14.9M
202117.5M19.5M21.4M23.5M
20203.9M6.6M9.9M15.1M
20192.1M2.2M2.4M2.0M
2018370.0K745.0K1.2M2.0M
2017684.0K1.1M1.4M1.1M
2016000317.0K
2015000317.0K

Tracking the Latest Insider Buys and Sells of Syros Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 05, 2024
eckhardt sue gail
acquired
-
-
4,000
-
Jun 05, 2024
oh andrew m.
acquired
-
-
4,000
-
Jun 05, 2024
young richard a
acquired
-
-
4,000
-
Jun 05, 2024
simonian nancy a
acquired
-
-
4,000
-
Jun 05, 2024
fanucci marsha
acquired
-
-
4,000
-
Jun 05, 2024
tyson timothy
acquired
-
-
4,000
-
Jun 05, 2024
wirth peter
acquired
-
-
4,000
-
Jun 01, 2024
dunsire deborah
acquired
-
-
4,000
-
Jun 01, 2024
akkaraju srinivas
acquired
-
-
4,000
-
Apr 03, 2024
roth david
sold
-51,732
4.95
-10,451
chief medical officer

1–10 of 50

Which funds bought or sold SYRS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 29, 2024
Opaleye Management Inc.
added
119
1,413,340
4,212,830
0.92%
May 20, 2024
Virtu Financial LLC
new
-
64,000
64,000
-%
May 17, 2024
Artal Group S.A.
unchanged
-
-6,112,180
13,401,800
0.34%
May 16, 2024
JANE STREET GROUP, LLC
added
716
758,324
922,966
-%
May 15, 2024
Steward Partners Investment Advisory, LLC
unchanged
-
-19.00
43.00
-%
May 15, 2024
MARSHALL WACE, LLP
added
543
660,442
853,775
-%
May 15, 2024
DAFNA Capital Management LLC
reduced
-36.78
-947,156
726,798
0.16%
May 15, 2024
Flagship Pioneering Inc.
added
-
-3,156,980
6,922,090
0.45%
May 15, 2024
683 Capital Management, LLC
sold off
-100
-283,899
-
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
new
-
61,792
61,792
-%

1–10 of 48

Are Funds Buying or Selling SYRS?

Are funds buying SYRS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SYRS
No. of Funds

Unveiling Syros Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
blue owl capital holdings lp
5.74%
1,493,252
SC 13G
Feb 13, 2024
ally bridge medalpha master fund l.p.
2.6%
570,976
SC 13G/A
Feb 13, 2024
bain capital life sciences fund ii, l.p.
9.99%
2,749,808
SC 13G/A
Feb 13, 2024
avidity partners management lp
9.9%
2,662,206
SC 13G/A
Feb 09, 2024
artal international s.c.a.
9.9%
3,568,842
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
9.99%
2,623,984
SC 13G/A
Jan 02, 2024
point72 asset management, l.p.
5.7%
1,471,771
SC 13G
Dec 26, 2023
samsara biocapital, l.p.
9.5%
2,493,541
SC 13D/A
Oct 20, 2023
samsara biocapital, l.p.
7.4%
1,588,564
SC 13D
Feb 14, 2023
bain capital life sciences fund ii, l.p.
9.99%
2,124,694
SC 13G/A

Recent SEC filings of Syros Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 06, 2024
8-K
Current Report

Peers (Alternatives to Syros Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
21.0B
2.0B
9.73% -16.82%
-63.12
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.43
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.37
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.82
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.24
14.45
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.69
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Syros Pharmaceuticals Inc News

Latest updates
Yahoo Finance17 Jun 202411:34 am

Syros Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-89.7%3873,7622,8332,9543,4233,8916,2765,4677,8025,6975,1624,8275,6983,8283,1882,379508558462454893
Operating Expenses-28.3%27,52738,39836,83336,16635,24343,34540,04532,12033,22632,60831,30625,76834,91822,82519,92919,71820,67920,94720,67017,42719,500
  S&GA Expenses-24.2%5,8887,7647,2257,4057,3298,0766,9456,9496,4315,3465,5205,7395,8925,1515,1335,1496,4025,0165,1954,8654,372
  R&D Expenses-24.0%21,50428,28029,60828,76127,91425,75933,10025,17126,79527,26225,78620,02929,02617,67414,79614,56914,27715,93115,47512,56215,128
Interest Expenses2.0%1,3291,3031,2781,2171,1261,05198197698798496996754149348727120.0021.0023.008.00-
Income Taxes----------------7.00-----
Net Income-60.4%-64,384-40,143-36,258-23,789-4,774-30,253-34,481-25,146-23,813-26,027-22,490-14,228-30,130-19,486-17,196-17,226-19,729-19,793-19,455-16,461-18,032
Net Income Margin-76.3%-16.56*-9.40*-7.66*-6.84*-6.36*-4.85*-4.34*-4.04*-3.69*-4.34*-4.42*----------
Free Cashflow41.6%-18,600-31,858-22,385-37,136-31,757-36,115-26,289-30,145-23,214-28,437-26,882----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-19.9%13516814818120524428512615218320823411021313314816115014415288.00
  Current Assets-22.6%11214512315317421125292.0011613715318611017999.0011212611511112478.00
    Cash Equivalents-40.1%84.0014011211510517115.0059.0070.0095.0011916422517493.0010911745.0033.0010222.00
  Net PPE-4.6%7.007.008.0010.0011.0011.0012.0012.0013.0013.0013.0014.0014.0014.0015.0015.0016.0015.0011.005.004.00
  Current Liabilities1.7%37.0037.0028.0028.0024.0031.0038.0039.0028.0032.0030.0028.006.0029.0028.0023.0020.0024.0023.0015.0015.00
  Long Term Debt-14.0%30.0035.0039.0041.0039.0041.0041.0034.0039.0040.0040.0040.0040.0040.0020.0020.0020.00----
    LT Debt, Current75.0%12.007.002.00-2.00--7.002.00------------
    LT Debt, Non Current-14.0%30.0035.0039.0041.0039.0041.0041.0034.0039.0040.0040.0040.0040.0040.0020.0020.0020.00----
Shareholder's Equity-9.6%15.0017.0036.0073.0010712812931.0063.0085.0010613015091.0046.0062.0019.0079.0095.0011264.00
  Retained Earnings-0.5%-726-722-658-618-582-558-553-523-488-463-439-413-136-377-346-327-310-292-273-253-234
  Additional Paid-In Capital0.3%742739695691688686683554552549546544239468393390387372368365298
Shares Outstanding1.1%27.0026.0021.0021.0028.0020.009.006.006.006.006.006.00---------
Float----59.00---56.00---311---442,689---351,070-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-67.5%-31,098-18,562-31,858-22,386-36,901-31,083-35,787-26,178-30,017-22,969-28,127-26,454-21,990-29,924-15,255-12,431246-10,603-11,224-18,099-20,327
  Share Based Compensation22.3%2,1031,7203,2552,8142,6452,9032,9552,6892,8632,8752,0962,4532,9303,0302,7232,7272,4593,2162,3892,3551,879
Cashflow From Investing-1718.9%-24,6401,52228,64032,923-25,74837,7216,19215,8897,383-245-17,301-34,845-262-29.00-5224,01243,20316,953-57,14032,682-4,229
Cashflow From Financing-100.6%-26543,380-5.00140-53.00-10,703142,064-223-93.0096.00-67.0072.0070,410110,80423622031,6931,089-12.0065,028-115
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SYRS Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue $ 2,954
Operating expenses:  
Research and development$ 24,65528,761
General and administrative6,2667,405
Total operating expenses30,92136,166
Loss from operations(30,921)(33,212)
Interest income1,5461,775
Interest expense(1,307)(1,217)
Change in fair value of warrant liabilities26,9748,865
Net loss applicable to common stockholders$ (3,708)$ (23,789)
Net loss per share applicable to common stockholders - basic$ (0.1)$ (0.85)
Net loss per share applicable to common stockholders - diluted$ (0.1)$ (0.85)
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic38,978,04627,842,218
Weighted-average number of common shares used in net loss per share applicable to common stockholders - diluted38,978,04627,842,218

SYRS Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 83,523$ 139,526
Marketable securities24,781 
Prepaid expenses and other current assets3,8985,454
Total current assets112,202144,980
Property and equipment, net6,9647,298
Other long-term assets1,5501,592
Restricted cash2,1192,119
Right-of-use asset – operating lease11,89312,185
Total assets134,728168,174
Current liabilities:  
Accounts payable11,34611,544
Accrued expenses11,88116,146
Operating lease obligation, current portion2,4092,324
Debt, current portion11,6676,667
Total current liabilities37,30336,681
Operating lease obligation, net of current portion17,88718,528
Warrant liabilities34,77361,747
Debt, net of debt discount, net of current portion29,70834,556
Commitments and contingencies (See Note 9)
Stockholders' equity:  
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value; 70,000,000 shares authorized at March 31, 2024 and December 31, 2023; 26,728,337 and 26,448,678 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively2626
Additional paid-in capital741,546739,443
Accumulated deficit(726,515)(722,807)
Total stockholders' equity15,05716,662
Total liabilities and stockholders' equity$ 134,728$ 168,174
SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEsyros.com
 INDUSTRYBiotechnology
 EMPLOYEES117

Syros Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Syros Pharmaceuticals Inc? What does SYRS stand for in stocks?

SYRS is the stock ticker symbol of Syros Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Syros Pharmaceuticals Inc (SYRS)?

As of Fri Jun 21 2024, market cap of Syros Pharmaceuticals Inc is 149.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SYRS stock?

You can check SYRS's fair value in chart for subscribers.

What is the fair value of SYRS stock?

You can check SYRS's fair value in chart for subscribers. The fair value of Syros Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Syros Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SYRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Syros Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SYRS is over valued or under valued. Whether Syros Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Syros Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SYRS.

What is Syros Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, SYRS's PE ratio (Price to Earnings) is -1.03 and Price to Sales (PS) ratio is 15.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SYRS PE ratio will change depending on the future growth rate expectations of investors.